Yesterday, Nov. 3, 2015, 89 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $9.84 to $10,914,626.52.

Highlighted Stocks Traded by Insiders:

Seventy Seven Energy (SSE) - FREE Research Report

Ogilvie Marran H., who is Director at Seventy Seven Energy, bought 44,700 shares at $1.25 on Nov. 3, 2015. Following this transaction, the Director owned 89,431 shares meaning that the stake was boosted by 99.93% with the 44,700-share transaction.

The shares most recently traded at $1.44, up $0.19, or 13.02% since the insider transaction. Historical insider transactions for Seventy Seven Energy go as follows:

  • 4-Week # shares bought: 20,000
  • 12-Week # shares bought: 20,000
  • 24-Week # shares bought: 20,000

The average volume for Seventy Seven Energy has been 1.1 million shares per day over the past 30 days. Seventy Seven Energy has a market cap of $73.2 million and is part of the basic materials sector and energy industry. Shares are down 72.09% year-to-date as of the close of trading on Tuesday.

Seventy Seven Energy Inc. provides oilfield services in the United States. The company operates in four segments: Drilling, Hydraulic Fracturing, Oilfield Rentals, and Oilfield Trucking. Currently, there are 3 analysts who rate Seventy Seven Energy a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SSE - FREE

TheStreet Quant Ratings rates Seventy Seven Energy as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, poor profit margins, generally high debt management risk and generally disappointing historical performance in the stock itself. Get the full Seventy Seven Energy Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

China Biologic Products (CBPO) - FREE Research Report

Gao David, who is Chief Executive Officer at China Biologic Products, sold 12,891 shares at $112.26 on Nov. 3, 2015. Following this transaction, the Chief Executive Officer owned 472,991 shares meaning that the stake was reduced by 2.65% with the 12,891-share transaction.

The shares most recently traded at $114.94, up $2.68, or 2.33% since the insider transaction. Historical insider transactions for China Biologic Products go as follows:

  • 4-Week # shares sold: 131,118
  • 12-Week # shares sold: 162,226
  • 24-Week # shares sold: 5.5 million

The average volume for China Biologic Products has been 216,000 shares per day over the past 30 days. China Biologic Products has a market cap of $3.0 billion and is part of the health care sector and drugs industry. Shares are up 71.98% year-to-date as of the close of trading on Tuesday.

China Biologic Products, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. The company has a P/E ratio of 37.1. Currently, there are 3 analysts who rate China Biologic Products a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CBPO - FREE

TheStreet Quant Ratings rates China Biologic Products as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and impressive record of earnings per share growth. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full China Biologic Products Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Photronics (PLAB) - FREE Research Report

Tyson Mitchell G, who is Director at Photronics, sold 1,000 shares at $9.65 on Nov. 3, 2015. Following this transaction, the Director owned 68,579 shares meaning that the stake was reduced by 1.44% with the 1,000-share transaction.

The shares most recently traded at $9.81, up $0.16, or 1.61% since the insider transaction. Historical insider transactions for Photronics go as follows:

  • 4-Week # shares bought: 10,332
  • 4-Week # shares sold: 1,000
  • 12-Week # shares bought: 10,332
  • 12-Week # shares sold: 3,000
  • 24-Week # shares bought: 10,332
  • 24-Week # shares sold: 17,000

The average volume for Photronics has been 372,200 shares per day over the past 30 days. Photronics has a market cap of $649.7 million and is part of the technology sector and electronics industry. Shares are up 17.81% year-to-date as of the close of trading on Tuesday.

Photronics, Inc., together with its subsidiaries, manufactures and sells photomasks in the United States. Photomasks are high precision photographic quartz plates containing microscopic images of electronic circuits. The company has a P/E ratio of 22.1. Currently, there are 4 analysts who rate Photronics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PLAB - FREE

TheStreet Quant Ratings rates Photronics as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Photronics Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.